Status:
RECRUITING
Identifying Prognostic Variables for Persistent Upper Limb Dysfunctions After Breast Cancer Treatment
Lead Sponsor:
KU Leuven
Collaborating Sponsors:
Universitaire Ziekenhuizen KU Leuven
Vrije Universiteit Brussel
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Breast cancer is the most frequently occurring cancer, assuming that it accounts for 29% of all new cancers in women (European Cancer Information System). The number of long-term survivors is increasi...
Eligibility Criteria
Inclusion
- Patients scheduled for surgery (mastectomy or breast conserving surgery; in combination with axillary lymph node dissection or sentinel node biopsy) for unilateral primary breast cancer or patients with oligometastatic breast cancer.
- Patients with a cognitive and language functioning enabling coherent Dutch communication between the examiner and the participant
- Patients who can comply with the protocol at baseline assessment and willing to provide written informed consent
Exclusion
- BCS with widespread distance metastases, previous breast surgery, or planned bilateral surgery
- And/or with a diagnosis of a neurological or rheumatological condition,
- And/or BCS who are not available the entire duration of the study
Key Trial Info
Start Date :
April 26 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05297591
Start Date
April 26 2022
End Date
February 1 2025
Last Update
May 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitair Ziekenhuis Leuven
Leuven, Belgium, 3000